Q3 2024 Earnings Estimate for Sarepta Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Stock analysts at Leerink Partnrs increased their Q3 2024 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a note issued to investors on Wednesday, May 1st. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will post earnings of $1.39 per share for the quarter, up from their prior forecast of $1.37. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.13 per share. Leerink Partnrs also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $4.20 EPS, FY2024 earnings at $5.88 EPS and FY2025 earnings at $11.58 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.32% and a net margin of 1.20%. The firm had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. During the same period in the previous year, the firm earned ($1.44) EPS. The business’s quarterly revenue was up 63.1% on a year-over-year basis.

SRPT has been the topic of a number of other reports. Wedbush reissued an “outperform” rating and issued a $224.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Evercore ISI lifted their price objective on Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a research note on Tuesday, February 20th. Citigroup lifted their price objective on Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. JPMorgan Chase & Co. reduced their price objective on Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Barclays lifted their price objective on Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $160.60.

Sarepta Therapeutics Stock Up 2.3 %

SRPT stock opened at $133.66 on Friday. The business’s 50-day moving average price is $125.69 and its 200-day moving average price is $110.70. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $159.89. The stock has a market cap of $12.63 billion, a P/E ratio of -21.84 and a beta of 0.95.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Central Pacific Bank Trust Division acquired a new position in shares of Sarepta Therapeutics in the first quarter valued at about $414,000. Nordea Investment Management AB increased its holdings in shares of Sarepta Therapeutics by 120.6% in the first quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company’s stock valued at $8,004,000 after purchasing an additional 33,711 shares during the period. Connecticut Wealth Management LLC acquired a new position in shares of Sarepta Therapeutics in the first quarter valued at about $261,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Sarepta Therapeutics by 111.3% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 90,945 shares of the biotechnology company’s stock valued at $12,131,000 after purchasing an additional 47,895 shares during the period. Finally, Van ECK Associates Corp increased its holdings in shares of Sarepta Therapeutics by 5.3% in the first quarter. Van ECK Associates Corp now owns 86,329 shares of the biotechnology company’s stock valued at $11,176,000 after purchasing an additional 4,374 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the sale, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,815,030. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the transaction, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The disclosure for this sale can be found here. Insiders sold 22,096 shares of company stock worth $2,739,419 in the last three months. 7.40% of the stock is owned by insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.